Epigenetic resetting of human pluripotency
The Company of Biologists
MetadataShow full item record
Smith, A., Guo, G., Rostovskaya, M., Clarke, J., Dietmann, S., Myers, S., Bertone, P., & et al. (2017). Epigenetic resetting of human pluripotency. Development, 144 (15), 2748-2763. https://doi.org/10.1242/dev.146811
Much attention has focussed on the conversion of human pluripotent stem cells (PSCs) to a more naïve developmental status. Here we provide a method for resetting via transient histone deacetylase inhibition. The protocol is effective across multiple PSC lines and can proceed without karyotype change. Reset cells can be expanded without feeders with a doubling time of around 24 h. WNT inhibition stabilises the resetting process. The transcriptome of reset cells diverges markedly from that of primed PSCs and shares features with human inner cell mass (ICM). Reset cells activate expression of primate-specific transposable elements. DNA methylation is globally reduced to a level equivalent to that in the ICM and is non-random, with gain of methylation at specific loci. Methylation imprints are mostly lost, however. Reset cells can be re-primed to undergo tri-lineage differentiation and germline specification. In female reset cells, appearance of biallelic X-linked gene transcription indicates reactivation of the silenced X chromosome. On reconversion to primed status, $XIST$-induced silencing restores monoallelic gene expression. The facile and robust conversion routine with accompanying data resources will enable widespread utilisation, interrogation, and refinement of candidate naïve cells.
pluripotent stem cells, differentiation, human embryo, methylome, reprogramming
This research is funded by the Medical Research Council of the United Kingdom (MR/P00072X/1) and European Commission Framework 7 (HEALTH-F4-2013-602423, PluriMes), and in part by the UK Regenerative Medicine Platform (MR/L012537/1). WR is supported by the BBSRC (BB/K010867/1), Wellcome Trust (095645/Z/11/Z), EU BLUEPRINT, and EpiGeneSys. The Cambridge Stem Cell Institute receives core funding from the Wellcome Trust and the Medical Research Council. FvM was funded by a Postdoctoral Fellowship from the Swiss National Science Foundation (SNF)/Novartis. SM is funded by a Wellcome Trust PhD Studentship. AS is a Medical Research Council Professor.
Wellcome Trust (097922/Z/11/Z)
European Commission (602423)
Embargo Lift Date
External DOI: https://doi.org/10.1242/dev.146811
This record's URL: https://www.repository.cam.ac.uk/handle/1810/264753
Attribution 4.0 International
Licence URL: http://creativecommons.org/licenses/by/4.0/